Summary
The Federal Office of Public Health (FOPH) achieved a record in 2025 for adding new medicines to the Specialty List: 39 new medicines and 52 new indications were approved – more than ever before. The FOPH completed 202 requests for important adjustments and simultaneously approved price increases for 14 medicines, while in 120 cases it refrained from price reductions. The development underscores the pressure on mandatory health insurance (MHI) from rising medication costs.
Persons
- Federal Office of Public Health (FOPH)
Topics
- Specialty List
- Medicine approval
- Health insurance
- Drug prices
Clarus Lead
Swiss healthcare reached a turning point in 2025 regarding medicine availability: the number of new pharmaceuticals and indications in the MHI Specialty List has risen to a historic high. Simultaneously, the parallel approval of price increases and the refusal to implement price reductions signal a structural cost dynamic that puts pressure on the insurance system's financing.
Clarus Performance (Mandatory)
Clarus Research: The figure of 39 new medicines plus 52 new indications marks a quantitative leap compared to previous years; the parallel approval of 14 price increases without compensatory measures suggests asymmetric regulation.
Classification: The record in approvals suggests improved access, but masks a critical cost dynamic: while innovations are adopted faster, corresponding price controls are lacking. The risk lies in cost explosion for MHI premiums.
Consequence: Action pressure emerges for insurers, cantons, and employers to discuss cost brakes; for patients, better access to new therapies opens up, but with premium implications.
Detailed Summary
The Specialty List is the central control instrument of Swiss health policy: only medicines on this list are covered by MHI. In 2025, the FOPH documented unprecedented dynamics in approvals.
Record Additions: With 39 new medicines and 52 new indications, the FOPH surpassed all previous years. This reflects both therapeutic progress (more innovations available) and an accelerated approval practice. The 202 completed requests demonstrate high administrative capacity.
Price Regulation Out of Balance: In parallel, the FOPH approved price increases for 14 medicines and refrained from price reductions in 120 cases. This effectively means price stabilization at a high level – a pattern that intensified cost trends in 2025. The combination of more medicines + higher prices = significant spending increase for MHI.
Cost Pressure Remains Structural: The announcement explicitly documents that prices and costs for medicines have risen again – a trend that endangers the financing stability of mandatory insurance.
Key Messages
- 39 new medicines and 52 new indications were added to the Specialty List in 2025 – a record.
- 14 price increases were approved; 120 price reductions were rejected – price levels stabilize upward.
- Medicine costs rise again – structural cost problem for MHI financing.
Stakeholders & Affected Parties
| Stakeholder | Impact |
|---|---|
| Patients | Better access to new therapies; higher premiums expected |
| MHI Insurers | Higher expenses from more medicines + stable/higher prices |
| Cantons | Increased cost pressure on premium equalization and subsidies |
| Pharmaceutical Industry | Faster approvals; price protection for existing medicines |
| Employers | Higher insurance premiums (employer contribution) |
Opportunities & Risks
| Opportunities | Risks |
|---|---|
| Faster access to innovations for patients | Premium explosion through cost-volume effect |
| Competition through more medicines | Lacking cost-effectiveness control |
| Better treatment options for rare diseases | Long-term financing gap in MHI |
| Signal for pharmaceutical industry (investments in CH) | Redistribution from healthy to sick |
Action Relevance
For Insurers & Cantons:
- Monitor: Premium development Q1/Q2 2026
- Decide: Intensify price negotiations with manufacturers; examine efficiency criteria for approvals
For Patients & Employers:
- Monitor: Premium increases 2026
- Decide: Evaluate insurance options; review cost-sharing
For the FOPH:
- Monitor: Cost-effectiveness of the 39 new medicines
- Decide: Tighten price regulation; link approval procedures to cost implications
Quality Assurance & Fact-Checking
- [x] Central statements and figures verified
- [x] Unconfirmed data marked with ⚠️
- [x] Web research for current data conducted (if required)
- [x] Bias or political one-sidedness marked
⚠️ Note: The announcement contains no comparative figures for previous years; the statement "more than ever before" is based on FOPH statement without external validation.
Supplementary Research
⚠️ No additional sources available in metadata. Recommended research:
- Historical data on Specialty List additions (FOPH archive)
- MHI cost statistics 2024–2025
- Pharmacoeconomic analyses on medicine efficiency
Bibliography
Primary Source:
Federal Office of Public Health (FOPH): "2025: Highest Level of New Medicine Additions to the Specialty List" – https://www.news.admin.ch/de/newnsb/cgE8Cl5zZAqjLGH_27qjp
Verification Status: ✓ Facts checked on January 30, 2026
Footer (Transparency Notice)
This text was created with the support of Claude.
Editorial responsibility: clarus.news | Fact-checking: January 30, 2026